Immunomodulation of multiple myeloma

Cancer Biology and Therapy

Volumn 3, Issue 11, 2004, Pages 1060-1061

  Tohnya, Tanyifor M ^b   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

Angiogenesis; CC 4047; Immunomodulation; Multiple myeloma; Thalidomide

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 6; LENALIDOMIDE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR;

ANGIOGENESIS; APOPTOSIS; CANCER RELAPSE; CELL GROWTH; CELL STIMULATION; CLINICAL TRIAL; CONSTIPATION; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; FATIGUE; HUMAN; IMMUNOMODULATION; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL NEUROPATHY; SHORT SURVEY; SOMNOLENCE; T LYMPHOCYTE; TERATOGENICITY; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MULTIPLE MYELOMA;

EID: 22144441750     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.11.1303     Document Type: Short Survey

References (14)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002; 52:23-47.
2. Kuehl WM, Bergsagel Pl. Multiple Myeloma: evolving gentle events and host interactions. Nat Rev Cancer 2002; 2:175-87.
3. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haemotol 2003; 120:10-17.
4. Sirohi B, Powles R. Multiple myeloma. Lancet 2004; 363:875-87.
5. Brunner G, Nguyen H, Gabrilove J, Rifkin DB, Wilson EL. Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993; 81:631-8.
6. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86:356-61.
7. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA, 1994; 91:4082-5.
8. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64:971-8.
9. Fine HA, Figg WD, Jaeckle K, Wen PY. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-15.
10. Little RF, Wyvill KM, Pluda JM, Welles L. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000; 18:2593-602.
11. Richardson P, Anderson K. Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol 2004; 22: 3212-4.
12. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalgleish AG. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004; 22:3269-76.
13. Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI, Zeldis J, Dalgleish AG. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004; 90:955-61.
14. Dredge K, Marriott JB, Macdonald CD, Man HW, Chen R, Muller GW, Stirling D, Dalgleish AG. Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer 2002; 87:1166-72.